Home >> Tag Archives: NeoGenomics—

Tag Archives: NeoGenomics—

NeoGenomics to acquire Genoptix

Oct. 26, 2018—NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach, and leaving us better positioned for growth,” Douglas M. VanOort, NeoGenomics’ chairman ...

Read More »

NeoGenomics to host molecular symposium

Dec. 28, 2017—NeoGenomics will host a symposium, “NGS for Clinicians and Pathologists: An Overview of Principles and Clinical Applications,” Feb. 23–24, 2018 at Laguna Cliffs Marriott Resort and Spa, Dana Point, Calif. Objectives of the symposium are to simplify next-generation sequencing for clinicians and pathologists with discussion of its advantages, disadvantages, and pitfalls; provide an introduction to NGS data analysis software ...

Read More »

Cell-free DNA tests, 2/16

February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.

Read More »

NeoGenomics acquires Clarient, 12/15

December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.

Read More »

NeoGenomics offers two new cfDNA tests

Dec. 11, 2015—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies. The NeoLab Solid Tumor Monitor is designed to quantify and track genomic abnormalities in tumors ...

Read More »

NeoGenomics buys GE’s Clarient

Nov. 2, 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly-owned subsidiary Clarient Diagnostic Services, which provides cancer diagnostic testing to hospitals, physicians, and the pharmaceutical industry. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Aliso Viejo, Calif., and Houston, and has about 415 employees. Clarient had 2014 revenue of $127 million. NeoGenomics said ...

Read More »

NeoGenomics offers cervical FISH panel

Oct. 5, 2015—NeoGenomics Laboratories has introduced the the NeoSite Cervical FISH Panel to aid diagnosis, classification, and monitoring progression and regression of cervical lesions including ASCUS, LSIL, HSIL, and CIN. Global and tech-only testing is now available. The NeoSite Cervical FISH Panel, performed on ThinPrep® cytology samples, serves as an adjunct to cytology and HPV nucleic acid analysis. The panel ...

Read More »
X